WO1996009074B1 - Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell - Google Patents
Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cellInfo
- Publication number
- WO1996009074B1 WO1996009074B1 PCT/US1995/011456 US9511456W WO9609074B1 WO 1996009074 B1 WO1996009074 B1 WO 1996009074B1 US 9511456 W US9511456 W US 9511456W WO 9609074 B1 WO9609074 B1 WO 9609074B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- promoters
- genome
- promoter
- gene
- nucleic acid
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 44
- 241000700605 Viruses Species 0.000 title claims abstract 23
- 210000004962 mammalian cell Anatomy 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 claims abstract 34
- 238000000034 method Methods 0.000 claims abstract 13
- 241000701447 unidentified baculovirus Species 0.000 claims abstract 10
- 241000124008 Mammalia Species 0.000 claims abstract 4
- 230000007812 deficiency Effects 0.000 claims abstract 2
- 108020004707 nucleic acids Proteins 0.000 claims 30
- 102000039446 nucleic acids Human genes 0.000 claims 30
- 150000007523 nucleic acids Chemical class 0.000 claims 30
- 108020004414 DNA Proteins 0.000 claims 8
- 241000238631 Hexapoda Species 0.000 claims 7
- 108090000364 Ligases Proteins 0.000 claims 6
- 102000003960 Ligases Human genes 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 102000004452 Arginase Human genes 0.000 claims 5
- 108700024123 Arginases Proteins 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 4
- 108010001831 LDL receptors Proteins 0.000 claims 4
- 102000000853 LDL receptors Human genes 0.000 claims 4
- 108020004440 Thymidine kinase Proteins 0.000 claims 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 108090000489 Carboxy-Lyases Proteins 0.000 claims 3
- 102000004031 Carboxy-Lyases Human genes 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 3
- 108010076282 Factor IX Proteins 0.000 claims 3
- 102100029115 Fumarylacetoacetase Human genes 0.000 claims 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 3
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 claims 3
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims 3
- 108090000856 Lyases Proteins 0.000 claims 3
- 102000004317 Lyases Human genes 0.000 claims 3
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 3
- 208000012583 Menkes disease Diseases 0.000 claims 3
- 102000019010 Methylmalonyl-CoA Mutase Human genes 0.000 claims 3
- 108010051862 Methylmalonyl-CoA mutase Proteins 0.000 claims 3
- 101710169105 Minor spike protein Proteins 0.000 claims 3
- 101710081079 Minor spike protein H Proteins 0.000 claims 3
- 102100030626 Myosin-binding protein H Human genes 0.000 claims 3
- 101710139548 Myosin-binding protein H Proteins 0.000 claims 3
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims 3
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims 3
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims 3
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims 3
- 102000014750 Phosphorylase Kinase Human genes 0.000 claims 3
- 108010064071 Phosphorylase Kinase Proteins 0.000 claims 3
- 102000009097 Phosphorylases Human genes 0.000 claims 3
- 108010073135 Phosphorylases Proteins 0.000 claims 3
- 102100034391 Porphobilinogen deaminase Human genes 0.000 claims 3
- 108010053763 Pyruvate Carboxylase Proteins 0.000 claims 3
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 claims 3
- 102000006601 Thymidine Kinase Human genes 0.000 claims 3
- 208000018839 Wilson disease Diseases 0.000 claims 3
- 102000006995 beta-Glucosidase Human genes 0.000 claims 3
- 108010047754 beta-Glucosidase Proteins 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- ILRYLPWNYFXEMH-UHFFFAOYSA-N cystathionine Chemical compound OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 claims 3
- 229960004222 factor ix Drugs 0.000 claims 3
- 108010022687 fumarylacetoacetase Proteins 0.000 claims 3
- 230000002440 hepatic effect Effects 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 2
- 102000001690 Factor VIII Human genes 0.000 claims 2
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 claims 2
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 claims 2
- 108010015451 Glutaryl-CoA Dehydrogenase Proteins 0.000 claims 2
- 102100028603 Glutaryl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000004327 Glycine dehydrogenase (decarboxylating) Human genes 0.000 claims 2
- 108090000826 Glycine dehydrogenase (decarboxylating) Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 2
- 108010085747 Methylmalonyl-CoA Decarboxylase Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010035004 Prephenate Dehydrogenase Proteins 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229940047124 interferons Drugs 0.000 claims 2
- 150000004715 keto acids Chemical class 0.000 claims 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 241001203868 Autographa californica Species 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108010075016 Ceruloplasmin Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims 1
- 102000000989 Complement System Proteins Human genes 0.000 claims 1
- 108010069112 Complement System Proteins Proteins 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 1
- 108050005077 Haptoglobin Proteins 0.000 claims 1
- 102000014702 Haptoglobin Human genes 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 108010061952 Orosomucoid Proteins 0.000 claims 1
- 102000012404 Orosomucoid Human genes 0.000 claims 1
- 102100038124 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 102000013009 Pyruvate Kinase Human genes 0.000 claims 1
- 108020005115 Pyruvate Kinase Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000009190 Transthyretin Human genes 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- -1 factor vni Proteins 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000003125 jurkat cell Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 101150066555 lacZ gene Proteins 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 210000003098 myoblast Anatomy 0.000 claims 1
- 102000042567 non-coding RNA Human genes 0.000 claims 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 claims 1
- 101150066583 rep gene Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims 1
Abstract
Disclosed is a method of expressing an exogenous gene in a mammalian cell, involving infecting the cell with a non-mammalian virus, such as a baculovirus, whose genome carries an exogenous gene, and growing the cell under conditions such that the gene is expressed. Exogenous genes are delivered to mammalian cells by use of a transfer vector such as that described in the figure. Also disclosed is a method of treating a gene deficiency disorder in a mammal by providing to a cell a therapeutically effective amount of a virus whose genome carries an exogenous gene and growing the cell under conditions such that the exogenous gene is expressed in the mammal.
Claims
AMENDED CLAIMS
[received by the International Bureau on 25 March 1996 (25.03.96); original claims 18 and 58 amended; new claims 63-103 added;
remaining claims unchanged (9 pages)]
10. The method cf claim.5, wherein said
baculovirus is in the budded form.
11. The method of claim 1, wherein said genome further comprises a promoter of a long-terminal repeat of a transposable element.
12. The method of claim 1, wherein said genome further comprises a promoter of a long-terminal repeat of a rerrovirus.
13. The method of claim 12, wherein said retrovirus is Rous Sarmoma Virus.
14. The method of claim 1, wherein said genome further comprises an integrative terminal repeat of an adeno-associated virus.
15. The method or claim 14, wherein said genome further comprises an adeno-associated virus rep gene.
16. The method of claim 1, wherein said genome further comprises a cell-immortalizing sequence.
17. The method of claim 1, wherein said genome further comprises an origin of replication. 18. The method of claim 17, wherein said origin of replication comprises an Epstein Barr virus origin of replication.
19. The method of claim 1, wherein said genome further comprises a polyadenylaticn signal and an RNA splicing signal.
medicament for treating a gene deficiency disorder in a mammal.
55. The use of claim 54, wherein said virus is an invertebrate virus. 56. The use of claim 55, wherein said
invertebrate virus is an insect virus.
57. The use of claim 56, wherein said insect virus is a baculovirus.
58. The use of claim 54, wherein said gene encodes a gene product selected from the group consisting of fumarylacetoacetate hydrolase, phenylalanine
hydroxylase, alpha-1 antitrypsin, glucose-6-phosphatese, low-density-lipoprotein receptor, porphobilinogen
deaminase, carbamoyl synthetase I, ornithine
transcarbamylase, arginosuccinate synthetase,
arginosuccinate lyase. arginase, factor VIII, factor IX, cystathione β-synthase, branched chain ketoacid
decarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl CoA. carboxylase, methyl malonyl CoA mutase, glucaryl CoA dehydrogenase, insulin, β-glucosidase, and pyruvate carboxylase, hepatic phosphorylase,
phosphorylase Kinase, glycine decarboxylase, H-protein, T-protein, Menkes disease protein, the product of
Wilson's disease gene pWD and CFTR. 59. Use of a non-mammalian DNA virus whose ganome comprises a carcinoma-therapeutic gene selected from the group consisting of tumor necrosis factor, thymidine kinase, diphtheria toxin chimeras, and cytosine diaminase in the preparation of a medicament for treating
hepatocellular carcinoma in a mammal.
60. The use of claim 59, wherein said non-mammalian DNA virus is a baculovirus.
61. The use of claim 59, wherein said carcinoma-tharapeutic gene is operably linked to an α-fetoprotein promoter.
62. The method of claim 1, wherein said exogenous gene is selected from the group consisting of lacZ genes, chloramphenicol acetyltransferase genes, alkaline phosphatase genes, luciferase genes, and green fluorescent protein genes.
63. A nucleic acid comprising:
a genome of a non-mammalian DNA virus;
an exogenous mammalian gene; and
an exogenous mammalian-active promoter, wherein said gene is operably linked to said promoter.
64. The nucleic acid of claim 63, wherein said genome is the genome of an insect virus.
65. The nucleic acid of claim 64, wherein said genome is the genome of a baculovirus.
66. The nucleic acid of claim 65, wherein said genome is the genome of an Autographa californica multiple nuclear
polyhedrosis virus.
67. The nucleic acid of claim 63, wherein said mammalian-active promoter is selected from the group consisting of
mammalian promoters, promoters of long-terminal repeats of retroviruses, promoters of long-terminal repeats of transposable
elements, the simian Virus 40 early promoter, the sytomegalovirus IE promoter, and the adenovirus major late promoter.
68. The nucleic acid of claim 67, wherein said promoter is a mammalian promoter.
69. The nucleic acid of claim 63, wherein said promoter is selected from the group consisting of cell-type-specific
promoters, stage-specific promoters, inducible promoters and tissue-specific promoters.
70. The nucleic acid of claim 69, wherein said promoter is a liver-specific promoter. 71. The nucleic acid of claim 70, wherein said liver-specific promoter is selected from the group consisting of hepatitis B promoters, hepatitis A promoters, hepatitis C
promoters, albumin promoters, α-1-antitrypsin promoters, pyruvate kinase promoters, phosphenol pyruvate carfaoxykinase promoters, transferrin promoters, transthyretin promoters, α-fetoprotein promoters, α-fibrinogen promoters, and β-fibrinogen promoters.
72. The nucleic acid or claim 70, wherein said liver- specific promoter is selected from the group consisting of low density lipoprotein receptor promoters, α2-macroglobulin
promoters, α1-antichymotrypsin promoters, α2-HS glycoproiein promoters, haptoglobin promoters, ceruloplasmin promoter;, plasminogen promoters, complement protein promoters, 63
complement activator promoters, β-lipoprotein promoters, and α1- acid glycoprotein promoters.
73. The nucleic acid of claim 63, further comprising a mammalian origin of replication.
74. The nucleic acid of claim 63, further comprising an integrative terminal repeat.
75. The nucleic acid of claim 63, wherein said genome lacks a functional polyhedron gene.
76. The nucleic acid of claim 63, wherein said gene is a human gene. 77. The nucleic acid of claim 63, wherein, said gene is a therapeutic gene.
78. The nucleic acid of claim 62, wherein said gene encodes a gene product selected from the group consisting of carbamoyl synthetase I, ornithine transcarbamylase, arginosuccinate
synthetase, arginosuccinate lyase. arginase fumarylacetoacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-6-phosphatase, low-density-lipoprotein receptor,
porphobilinogen deaminase, arginase, factor VIII, factor IX, cystathione β-sγnthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl coA dehydrogenase, insulin, β-glucosidase, and pyruvate carboxylase, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, Menkes disease protein, the product of Wilson's disease gene pWD, growth factors, interferons, CFTR, tumor suppressors, herpes simplex virus thymidine kinase, and transcription factors.
79. A nucleic acid comprising:
a genome of a non-mammalian DNA virus;
an exogenous antisense RNA gene, the RNA encoded by said gene being complementary to a nucleic acid of a gena that is expressed in a cell at an undesirably high level; and
an exogenous mammalian-active promoter, whereir said gene is operably linked to said promoter.
80. The nucleic acid of claim 79, wherein said genome is the genome of an insect virus.
81. The nucleic acid of claim 79, wherein said genome is the genome of a baculovirus. 82. The nucleic acid of claim 79, wherein said promoter is selected from the group consisting of mammalian promoters, promoters of long-terminal repeats of rerroviruses, and promoters of long-terminal repeats of transposable elements, the s mian Virus 40 early promoter, the cytomegalovirus IE promoter and the adenovirus major late promoter.
83. A cell that contains a nucleic acid, wherein said nucleic acid comprises:
a genome of a non-mammalian DNA virus;
an exogenous mammalian gene; and
an exogenous mammalian-active promoter, wherein said gene is operably linked to said promoter.
84. The cell of claim 83, wherein said genome is tie genome of an insect virus. 85. The cell of claim 85, wherein said genome is tie genome of a baculovirus.
86. The cell of claim 83, wherein said promoter is selected from the group consisting of mammalian promoters, promotsrs of long-terminal repeats or retroviruses, and promoters of long-terminal repeats of transposable elements, the Simian Virus 40
early promoter, the cytomegalovirus IE promoter, and the adenovirus major late promoter.
87. The cell of claim 83, wherein said cell is a primary cell.
88. The call of claim 83, wherein said cell is a human cell. 39. The cell of claim 83, wherein said cell is sel ected from the group consisting of hepatocytes, kidney cells, NIH3T3 cells, HeLa cells, Cos7 cells, C2C12 myctubes, C2C12 myoblasts, CHO/dhfr- cells, lung cells, and PC12 cells. 90. The cell of claim 89, wherein said cell is a hapatocyte selected from the group consisting of HepG2 cells, Sk-Hep-1 cells, Hep3B cells, FTO2B cells, and Hepa 1-6 cells.
91. The cell of claim 83, wherein said cell is selected from the group consisting of Ramos cells, Jurkat cells, HL60 cells, and K-562 cells.
92. The cell of claim 83, wherein said promoter is selected from the group consisting of cell-type-specific promoters, tissue-specific promoters, stage-specific promoters, and
inducible promoters.
93. The cell of claim 83, wherein said promoter is a liver-specific promoter.
54. The cell of claim 83 , wherein said gene is a human gene .
95. The call of claim 83, wherein said gene encoders a gene product selected from the group consisting ot carbamoyl
synthetase I, ornithine transcarbamylase, arginosuccinate
synthetase. arginosuccinate lyase, arginase fumarylacetoacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-6-phosphatase, low-density-lipoprotein receptor,
porphobilinogen deaminase, arginase, factor vni, factor IX, cystathione β-synthase, branched chain ketcacid decarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl coA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, β-glucosidase, and pyruvate carboxylase, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylaee, H-protein, β-protein, Menkes disease protein, the product of Wilson's disease gene pWD, growth factors, interferons, CPTR, tumor suppressors, herpes simplex virus thymidine kinase, and transcription factors.
96. A nucleic acid comprising:
a genome of a non-mammalian DNA virus;
an exogenous cancer therapeutic gene selected from the group consisting of tumor necrosis factor genes, thymidine kinase genes, chimeric diphtheria toxin genes, and cytosine dianinase genes; and
an exogenous mammalian-active promoter, wherein said gene is operably linked to said promoter.
97. The nucleic acid of claim 96, wherein said genome is the genome of an insect virus.
98. The nucleic acid of claim 97, wherein said genome is the genome of a baculovirus.
99. A nucleic acid comprising;
a genome of a non-nammalian DNA virus;
an exogenous gene selected from the group consisting of RNA decoy genes and ribozyme genes; and
an exogenous mammalian-active promoter. 100. The nucleic acid or claim 99, wherein said genome comprises the genome of a baculovirus.
101. A pharmaceutical composition comprising:
(A) a pharmaceutically acceptable excipient and
(B) a nucleic acid, said nucleic acid comprising:
a genome of a non-mammalian DNA virus;
an exogenous mammalian gene; and
an exogenous mammalian-active promoter, wherein said gene is operably linked to said promoter.
102. The pharmaceutical composition of claim 101, therein said cenome comprises the genome of an insect virus.
103. The pharmaceutical composition of claim 102, wherein said genome comprises the genome of a baculovirus.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU36750/95A AU702830B2 (en) | 1994-09-23 | 1995-09-08 | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| EP95934407A EP0785803A4 (en) | 1994-09-23 | 1995-09-08 | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| JP8510940A JPH10506530A (en) | 1994-09-23 | 1995-09-08 | Use of a non-mammalian DNA virus expressing foreign genes in mammalian cells |
| MXPA/A/1997/002132A MXPA97002132A (en) | 1994-09-23 | 1997-03-20 | Use of a non-myamiferous dna virus to express an exogenous gene in a mamif cell |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/311,157 | 1994-09-23 | ||
| US08/311,157 US5871986A (en) | 1994-09-23 | 1994-09-23 | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US08/486,341 | 1995-06-07 | ||
| US08/486,341 US5731182A (en) | 1994-09-23 | 1995-06-07 | Non-mammalian DNA virus to express an exogenous gene in a mammalian cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996009074A1 WO1996009074A1 (en) | 1996-03-28 |
| WO1996009074B1 true WO1996009074B1 (en) | 1996-05-09 |
Family
ID=26977767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/011456 WO1996009074A1 (en) | 1994-09-23 | 1995-09-08 | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6238914B1 (en) |
| EP (1) | EP0785803A4 (en) |
| JP (1) | JPH10506530A (en) |
| CN (1) | CN1172435A (en) |
| AU (1) | AU702830B2 (en) |
| CA (1) | CA2200835A1 (en) |
| IL (1) | IL115267A0 (en) |
| OA (1) | OA10408A (en) |
| TW (1) | TW464500B (en) |
| WO (1) | WO1996009074A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| CA2264966A1 (en) | 1996-09-11 | 1998-03-19 | The General Hospital Corporation | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
| US6183993B1 (en) | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
| AU4266597A (en) * | 1996-09-11 | 1998-04-14 | General Hospital Corporation, The | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| FR2756297B1 (en) * | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | PROCESS FOR PRODUCING RECOMBINANT VIRUSES |
| IT1291135B1 (en) * | 1997-04-08 | 1998-12-29 | Angeletti P Ist Richerche Bio | RECOMBINANT VECTORS USABLE IN GENE THERAPY |
| FR2761994B1 (en) * | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES |
| GB9708698D0 (en) * | 1997-04-29 | 1997-06-18 | Imperial College | Materials for therapy |
| US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
| DE19735593C2 (en) * | 1997-08-15 | 1999-08-26 | Hepavec Ag Fuer Gentherapie | Coat protein-modified baculovirus vector for gene therapy |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| US6933145B1 (en) | 1998-05-29 | 2005-08-23 | University Of Florida Research Foundation, Inc. | Materials and methods for delivery and expression of heterologous DNA in vertebrate cells |
| GB0119852D0 (en) * | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
| WO2003020322A1 (en) * | 2001-09-04 | 2003-03-13 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Vector used to induce an immune response |
| TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| JP2003286199A (en) * | 2002-03-29 | 2003-10-07 | Japan Science & Technology Corp | Therapeutic medicine for hepatic disease using protein hollow nanoparticle |
| JP2003286198A (en) * | 2002-03-29 | 2003-10-07 | Japan Science & Technology Corp | Therapeutic medicine using protein hollow nanoparticle expression growth factor, and the like |
| EP2301573A1 (en) * | 2002-10-01 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Anti-cancer and anti-infectious disease compositions and methods for using same |
| GB0425739D0 (en) * | 2004-11-23 | 2004-12-22 | Procure Therapeutics Ltd | Humanised baculovirus 2 |
| EP1869191B1 (en) * | 2005-03-22 | 2012-12-26 | Agency for Science, Technology and Research | Novel neural cell specific promoter and baculovirus and method for gene delivery |
| US20080044855A1 (en) * | 2006-03-22 | 2008-02-21 | Yan Xu | System for regulated and enhanced baculovirus mediated transient transgene expression in mammalian cells |
| FR2966841A1 (en) * | 2010-11-02 | 2012-05-04 | Inst Nat De Rech Agronomique Inra | VECTORS DERIVED FROM DENSOVIRUS FOR GENE TRANSFER IN INSECT |
| CN102199629A (en) * | 2011-03-29 | 2011-09-28 | 中国科学院武汉病毒研究所 | Method for improving transduction efficiency of rhabdovirus on mammalian cells |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2018217731A1 (en) | 2017-05-22 | 2018-11-29 | Baxalta Incorporated | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b |
| WO2019055457A1 (en) | 2017-09-12 | 2019-03-21 | Biocapital Holdings, Llc | Biological devices for producing oxidized zinc and applications thereof |
| JP2021512871A (en) | 2018-02-01 | 2021-05-20 | ホモロジー・メディシンズ・インコーポレイテッド | Adeno-associated virus compositions for restoring PAH gene function and how to use them |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
| CN112423786B (en) * | 2018-08-10 | 2024-03-22 | 南特生物公司 | Cell adjuvants for viral infection |
| TW202140791A (en) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | Methods of treating phenylketonuria |
| TW202208632A (en) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) * | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4879236A (en) * | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| FR2579224B1 (en) * | 1985-03-25 | 1987-05-22 | Genetica | PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN |
| US5004687A (en) * | 1985-05-21 | 1991-04-02 | University Of Georgia Research Foundation, Inc. | Insect virus vector with broadened host range |
| US5106741A (en) * | 1985-12-20 | 1992-04-21 | The Upjohn Company | Tissue plasminogen activator (TPA) analogs |
| US5476781A (en) * | 1991-02-19 | 1995-12-19 | University Of Florida Research Foundation, Inc. | Entomopoxvirus spheroidin gene sequences |
| DE4407859C1 (en) * | 1994-03-04 | 1995-03-02 | Max Planck Gesellschaft | Vector for liver-specific gene therapy |
| US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US5871986A (en) * | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
-
1995
- 1995-09-08 AU AU36750/95A patent/AU702830B2/en not_active Ceased
- 1995-09-08 EP EP95934407A patent/EP0785803A4/en not_active Withdrawn
- 1995-09-08 CA CA002200835A patent/CA2200835A1/en not_active Abandoned
- 1995-09-08 WO PCT/US1995/011456 patent/WO1996009074A1/en not_active Application Discontinuation
- 1995-09-08 JP JP8510940A patent/JPH10506530A/en active Pending
- 1995-09-08 CN CN95196379A patent/CN1172435A/en active Pending
- 1995-09-12 IL IL11526795A patent/IL115267A0/en unknown
- 1995-09-23 TW TW084109934A patent/TW464500B/en not_active IP Right Cessation
-
1996
- 1996-11-19 US US08/752,030 patent/US6238914B1/en not_active Expired - Lifetime
-
1997
- 1997-03-21 OA OA60981A patent/OA10408A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996009074B1 (en) | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell | |
| Furler et al. | Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons | |
| US5919652A (en) | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof | |
| CA2161136C (en) | Adenoviruses having modified fiber proteins | |
| Massie et al. | Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette | |
| Jooss et al. | Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver | |
| CA2278616C (en) | Adenoviruses having altered hexon proteins | |
| ES2231813T3 (en) | PACKAGING SYSTEMS FOR ADENOVIRUS RECOMBINANT IN MAN INTENDED FOR GENE THERAPY. | |
| US6156497A (en) | Recombinase-mediated generation of adenoviral vectors | |
| WO1995029993A1 (en) | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line | |
| US6686196B2 (en) | Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof | |
| US20030203480A1 (en) | Method of preparing a eukaryotic viral vector | |
| WO1996014875A9 (en) | Novel nucleic acid molecules comprising the prostate specific antigen (psa) promoter and uses thereof | |
| LIPKOWITZ et al. | Transduction of renal cells in vitro and in vivo by adeno-associated virus gene therapy vectors | |
| CA2300362A1 (en) | Coat-protein-modified baculovirus vector for gene therapy | |
| OA10408A (en) | Use of a non-mamalian dna virus to express an exogenous gene in a mammalian cell | |
| JP4386971B2 (en) | Recombinant adenoviral vector comprising a splicing sequence | |
| EP0999280A2 (en) | Episomally replicating vector, its preparation and use | |
| WO1998045462A1 (en) | Recombinant vectors derived from adeno-associated virus suitable for gene therapy | |
| EP0953054B1 (en) | Ehv-1 vectors | |
| CA2442144A1 (en) | A helper dependent adenoviral vector system and methods for using the same | |
| Fu et al. | A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus | |
| ES2248849T3 (en) | GENERATION OF REPLICATING MOLECULES "IN VIVO". | |
| Pettersson et al. | Organization and expression of papillomavirus genomes | |
| Kojima et al. | Generation of recombinant adenovirus vector with infectious adenoviral genome released from cosmid-based vector by simple procedure allowing complex manipulation |